6Clinical Development, Medivation, San Francisco, CA, USA. 7Medical Science, Astellas Pharma Global Development, Deerfield, IL, USA. 8Comprehensive ...
Annals of Oncology 25 (Supplement 4): iv255–iv279, 2014 doi:10.1093/annonc/mdu336.49
genitourinary tumours, prostate 802TiP
PROSPER: A PHASE 3 STUDY OF ENZALUTAMIDE IN NON-METASTATIC (M0) CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS
C.N. Sternberg1, K. Fizazi2, F. Saad3, N.D. Shore4, A. Heidenreich5, M. Hirmand6, F.G. Perabo7, Z. Khondker6, K. Modelska6, M. Hussain8 1 Padiglione Flajani, I Piano, Clinica Pio XI, Rome, ITALY 2 Dept. of Medicine, Institut Gustave Roussy, Villejuif, FRANCE 3 Department of Surgery, University of Montreal Hospital Center, Montreal, QC, CANADA 4 Urology, Carolina Urologic Research Center, Myrtle Beach, SC, USA 5 Urology Clinic, University Hospital Aachen, Aachen, GERMANY 6 Clinical Development, Medivation, San Francisco, CA, USA 7 Medical Science, Astellas Pharma Global Development, Deerfield, IL, USA 8 Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA
abstracts
Background: Prostate cancer growth is dependent on androgen receptor (AR) signaling. There is no standard of care for patients with M0 CRPC and most patients will eventually develop metastatic disease despite ongoing androgen deprivation therapy (ADT). In a recent study, patients with a PSA >8 ng/mL or PSA doubling time of
